Maria Mudryj, Ph.D.
Vice Chair of Education and Outreach
Prostate cancer, Bladder Cancer, Androgen Receptor, Retinoblastoma (RB) E2F transcription factors
Our laboratory is studying urological malignancies, which are commonly diagnosed and a leading cause of death due to cancer in Western civilization.
Early prostate cancers require androgen to survive and proliferate; this dependence is exploited in treatment for disseminated disease. Therefore, androgen ablation is the first line of therapeutic intervention. Although these regimens are initially effective, tumors ultimately recur due to reactivation of androgen receptor (AR) signaling, causing treatment failure and patient morbidity. Despite the importance of understanding androgen action in the prostate, little is understood about the mechanisms underlying androgen dependence, and the means by which the androgen requirement is bypassed in relapsed tumors.
Bladder cancer shows a striking gender disparity where men are three times more likely to develop the disease than woman. Development of treatments for this disease has lagged and there have been few advances in the field. The AR has a role in this malignancy as well, although molecular mechanisms underlying this AR dependence are currently unknown.
My lab is dedicated to delineating the molecular mechanisms that govern urological tumor growth to identify new targets and strategies to eliminate these diseases.
Elisabeth A. Messner, Thomas M. Steele, Maria Malvina Tsamouri, Allen C. Gao, Maria Mudryj, Paramita M. Ghosh. Alternate targets in Androgen Receptor based therapy in Prostate Cancer: the N-terminal and the DNA binding domains. Biomedicines, 2020 8(10) 422. doi: 10.3390/biomedicines8100422;
Kimberly Katleba, Alan P. Lombard, Maria M. Tsamouri, Kristine S. Nishida, Han Bit Baek, Stephen J. Libertini, Alexander Platero, Ai-Hong Ma, Chong-xian Pan, Paramita M. Ghosh, Maria Mudryj. “Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cells viability and induces apoptosis.” Cancer Letters, 2021 Apr 28;504:49-57. doi: 10.1016/j.canlet.2021.01.029. Epub 2021 Feb 4. PMID: 33549708
Zsofia Kiss, Maria Mudryj and Paramita M. Ghosh. Non-circadian aspects of BHLHE40 cellular function in cancer. 2020 Genes and Cancer, 11(1-2):1-19
Salma Siddiqui, Stephen J. Libertini, Christopher A. Lucas, Alan P. Lombard, Han Bit Baek, Kristine Nishida, Rachel Nakagawa, Thomas M. Steele, Frank U. Melgoza, Alexander Borowsky, Blythe P. Durbin-Johnson, LiHong Qi, Paramita M. Ghosh, and Maria Mudryj. The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells . Cancer Letters, 2020, 483, 12-21.
Han Bit Baek, Alan Lombard, Stephen Libertini, Aleida Fernandez-Rubio, Ruth Vinall, Regina Gandour-Edwards, Rachel Nakagawa, Kathleen Vidello, Kristine Nishida, Hiromi Wettersten, Yosef Landesman, Robert H. Weiss, Paramita M. Ghosh, Maria Mudryj. XPO1 inhibition by Selinexor induces potent cytotoxicity against high grade bladder malignancies . Oncotarget, 2018 9 (77), 34567-34581.
Leandro S. D’Abronzo, Michael E. Crapuchettes, Ryan E. Beggs, Ruth L. Vinall, Clifford G. Tepper, Salma Siddiqui, Maria Mudryj, Frank E. Melgoza, Blythe P. Durbin-Johnson, Ralph W. deVere White and Paramita M. Ghosh. The Androgen Receptor is a negative regulator of eIF4E Phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer. Oncogene, 2017 46, 6359-6373.
Alan P. Lombard and Maria Mudryj. The Emerging role of the androgen receptor in bladder cancer. Endocrine-related cancer. 2015 Jul 30. pii: ERC-15-0209. [Epub ahead of print]
Alan P. Lombard, Rebecca Lim, Rachel Nakagawa, Kathleen Vidallo, Stephen J. Libertini, Alexander J. Platero, Maria Mudryj. Dicer Ablation Promotes a Mesenchymal and Invasive Phenotype in Bladder Cancer Cells. Oncology Reports 2015 Jul 9. doi: 10.3892/or.2015.4117.
Alan P. Lombard, Benjamin Mooso, Stephen J. Libertini, Rebecca Lim, Rachel Nakagawa, Kathleen Vidello, Nicole Constanzo. Paramita M. Ghosh, Maria Mudryj. MiR-148a dependent apoptosis of bladder cancer cells is mediated by the epigenetic modifier DNMT1. Molecular Carcinogenesis 11 APR 2015 DOI: 10.1002/mc.22319
Rosalinda M. Savoy, Liqun Chen, Salma Siddiqui, Frank U. Melgoza, Blythe Durbin-Johnson, Christiana Drake, Maitreyee K. Jathal, Swagata Bose, Thomas M. Steele, Benjamin A. Mooso, Leandro S. D’Abronzo, William H. Fry, Kermit L. Carraway, III, Maria Mudryj, and Paramita M. Ghosh. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear Filamin A in prostate cancer. Endocrine-related Cancer 2015 Mar 10. pii: ERC-15-0021. [Epub ahead of print]
Benjamin A. Mooso, Ruth L. Vinall, Maria Mudryj M, Stanley, A., Ralph deVere White, Paramita, M. Ghosh. The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence. J. Urol. 2015 Jan; 193, 19-29. e-pub. Aug 23, 2014.